KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eli Lilly (LLY) Cost of Revenue (2016 - 2025)

Eli Lilly (LLY) has disclosed Cost of Revenue for 17 consecutive years, with $3.4 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue rose 40.28% year-over-year to $3.4 billion, compared with a TTM value of $11.1 billion through Dec 2025, up 31.29%, and an annual FY2025 reading of $11.1 billion, up 31.29% over the prior year.
  • Cost of Revenue was $3.4 billion for Q4 2025 at Eli Lilly, up from $3.0 billion in the prior quarter.
  • Across five years, Cost of Revenue topped out at $3.4 billion in Q4 2025 and bottomed at $1.4 billion in Q2 2022.
  • Average Cost of Revenue over 5 years is $2.0 billion, with a median of $1.9 billion recorded in 2021.
  • The sharpest move saw Cost of Revenue soared 59.84% in 2021, then fell 26.76% in 2022.
  • Year by year, Cost of Revenue stood at $2.1 billion in 2021, then dropped by 24.49% to $1.5 billion in 2022, then rose by 15.48% to $1.8 billion in 2023, then surged by 34.44% to $2.4 billion in 2024, then soared by 40.28% to $3.4 billion in 2025.
  • Business Quant data shows Cost of Revenue for LLY at $3.4 billion in Q4 2025, $3.0 billion in Q3 2025, and $2.4 billion in Q2 2025.